Does Harvard Pilgrim Health Care Cover Forteo (Teriparatide)?

What Is Forteo and Why Does Coverage Matter?

Forteo (teriparatide) is a 34-amino-acid recombinant fragment of human parathyroid hormone approved by the FDA on November 26, 2002 for postmenopausal women and men at high fracture risk, and for glucocorticoid-induced osteoporosis. [1] Its mechanism is anabolic rather than antiresorptive: daily subcutaneous injections stimulate osteoblast activity, increasing bone mineral density (BMD) faster than oral bisphosphonates in most head-to-head studies.

Why the price makes coverage decisions high-stakes

The list price of a 28-day supply of Forteo is approximately $3,200 to $3,800 as of 2024, placing it among the most expensive osteoporosis treatments available. [2] For most patients, coverage determinations directly control whether teriparatide is accessible at all. A prior authorization denial can delay treatment by weeks or months, during which fracture risk remains elevated.

Clinical context: who actually needs Forteo?

The Fracture Risk Assessment Tool (FRAX) is the standard starting point. [3] Patients with a 10-year major osteoporotic fracture probability above 20% or hip fracture probability above 3% typically qualify for pharmacologic treatment. Within that population, anabolic therapy with teriparatide is generally reserved for the highest-risk subset, defined by the American Association of Clinical Endocrinology (AACE) 2020 guidelines as patients with a T-score at or below -2.5 plus one or more fragility fractures, or a T-score at or below -3.0 regardless of fracture history. [4]

The AACE 2020 position statement explicitly states: "Anabolic therapy should be considered as initial treatment in very high-risk patients, particularly those with multiple vertebral fractures or very low BMD." [4] That clinical framing matters when writing a prior authorization letter.

How Harvard Pilgrim Health Care Formularies Work

Harvard Pilgrim Health Care (HPHC) is a regional not-for-profit insurer operating primarily in New England, with commercial, Medicare Advantage, and employer-sponsored plans. It does not publish a single universal formulary. Instead, each plan product (e.g., HMO, PPO, HDHP, Medicare Advantage HMO) carries its own drug list, tier structure, and utilization management rules. [5]

Specialty tier placement for teriparatide

Across HPHC plan types, teriparatide consistently lands in the specialty drug tier, which carries the highest cost-sharing. Under commercial plans, specialty-tier cost-sharing typically runs from 25% to 33% coinsurance after the deductible, or a flat copay that can exceed $150 to $300 per 28-day fill depending on the specific plan design.

For Medicare Advantage enrollees, teriparatide falls under Part D specialty tier rules. Under the standard 2025 Medicare Part D benefit structure, the catastrophic coverage phase (which kicks in after the $2,000 out-of-pocket cap established by the Inflation Reduction Act) significantly reduces cost-sharing burden for high-cost injectables like Forteo. [6]

Where to find your specific plan's formulary

The most reliable approach is to log into the HPHC member portal at harvardpilgrim.org and use the drug lookup tool with your exact plan name and group number. Formulary tiers and prior authorization requirements can differ between plans sold by the same insurer, so checking your plan-specific documents (the Evidence of Coverage or Summary of Benefits and Coverage) is the only definitive method.

Prior Authorization Requirements for Forteo Under Harvard Pilgrim

Prior authorization (PA) is required for Forteo under essentially every HPHC plan that covers it. The PA process is managed through HPHC's pharmacy benefit management structure and typically requires the prescribing clinician to submit clinical documentation through the insurer's online portal or by phone. [7]

Typical clinical criteria HPHC applies

While HPHC does not publish its internal clinical criteria as a public document, the criteria it applies are broadly consistent with criteria used by major commercial PBMs and are anchored in published clinical guidelines. Based on published osteoporosis treatment guidelines and standard industry practice, the PA submission typically needs to address: [4] [8]

• A confirmed diagnosis of osteoporosis by DXA (T-score at or below -2.5 at spine, total hip, or femoral neck)
• Documentation of high fracture risk using FRAX or clinical fracture history [3]
• Documented failure, contraindication, or intolerance to at least one oral bisphosphonate (most commonly alendronate 70 mg/week or risedronate 35 mg/week for a minimum of 6 to 12 months)
• Documentation that the patient's diagnosis falls within an FDA-approved indication (postmenopausal osteoporosis, male osteoporosis, or glucocorticoid-induced osteoporosis) [1]
• Confirmation that the patient has not previously completed a 24-month course of teriparatide, since the FDA label restricts lifetime use to 24 months [1]

Step therapy: the bisphosphonate hurdle

Step therapy, also called "fail-first" policy, requires a patient to try and fail a less expensive drug before the insurer will cover the preferred (more expensive) option. For teriparatide, HPHC and most comparable insurers require documentation of prior bisphosphonate therapy. [9]

This is scientifically controversial. The VERO trial (N=1,360) demonstrated that teriparatide produced a 56% lower incidence of new vertebral fractures compared to risedronate at 24 months (relative risk 0.44, 95% CI 0.29 to 0.68, P<0.001), suggesting that forcing very high-risk patients through bisphosphonate step therapy first may expose them to preventable fractures. [10]

AACE guidelines directly address this: "In patients at very high risk, initiating therapy with an anabolic agent rather than an antiresorptive may be appropriate to reduce fracture risk more rapidly." [4] That guideline statement can be quoted verbatim in a PA appeal letter as evidence that step therapy is clinically inappropriate for a specific patient.

What Clinical Documentation Strengthens a Forteo PA Request

A complete, well-organized prior authorization packet dramatically reduces the chance of a first-round denial. Clinicians submitting PA for Forteo under HPHC should compile the following before initiating the request. [7] [11]

DXA results and fracture history

Include the most recent DXA report with T-scores at spine and hip, ideally with a comparison scan if available to show bone loss trajectory. List all prior fragility fractures with dates and imaging confirmation where possible. A vertebral fracture assessment (VFA) from DXA, or a lateral spine X-ray showing existing vertebral compression fractures, adds meaningful weight. [8]

Bisphosphonate trial documentation

If the patient completed a bisphosphonate trial, document the drug name, dose, duration, and reason for transition (inadequate response defined as continued bone loss or fracture on therapy, intolerance such as esophagitis or atypical femur fracture concern, or contraindication such as eGFR below 30 mL/min/1.73m2). [12]

FRAX score and clinical narrative

Print and include the FRAX calculation with country-specific thresholds applied. [3] A one-to-two paragraph clinical narrative from the ordering physician explaining why teriparatide is medically necessary for this specific patient, referencing the AACE guidelines, [4] carries more weight than a checkbox form.

Laboratory values

Serum calcium, 25-hydroxyvitamin D, PTH, and renal function (eGFR) should be included. Hypercalcemia or significantly elevated baseline PTH may actually argue against teriparatide, so submitting labs that confirm these are within acceptable ranges strengthens the case. [1]

What Happens if Harvard Pilgrim Denies the Forteo PA?

A denial is not a final answer. The appeals process is a federally protected right for commercial plans governed by the Employee Retirement Income Security Act (ERISA) and for Medicare Part D plans governed by CMS rules. [13]

Level 1 internal appeal

File within the timeframe specified in the denial letter, typically 60 to 180 days for commercial plans. The appeal should include all original PA documentation plus the denial rationale. Add a rebuttal letter that cites the specific clinical guideline or trial data that contradicts the insurer's stated reason for denial. For example, if the denial states that bisphosphonate therapy was not adequately trialed, submit refill records, dispensing logs, and a physician attestation.

Expedited appeal for urgent cases

If a patient has recently sustained a vertebral fracture or has extremely low BMD (T-score at or below -3.5) with active fracture pain, an expedited appeal can be requested. Under federal rules, expedited appeals for commercial plans must receive a decision within 72 hours. [13]

External independent review

If the internal appeal is denied, patients covered under fully-insured commercial plans or Medicare Part D have the right to request an external independent review by a CMS-approved Independent Review Organization (IRO). IRO decisions that overturn the insurer's denial are binding on the insurer. [13]

State insurance commissioner complaint

Massachusetts residents (where HPHC is headquartered and most heavily enrolled) can file a complaint with the Massachusetts Division of Insurance if they believe the denial violated state coverage mandates or was procedurally improper. Massachusetts has a step therapy override law that requires insurers to grant exceptions when a prescribing physician determines that the required first-step drug is clinically inappropriate for the patient. [14]

Cost of Forteo With and Without Coverage

With Harvard Pilgrim coverage

For a commercially insured patient who has cleared PA, cost-sharing depends on the specific plan's specialty tier structure. A 28-day supply at 25% coinsurance after a $1,000 deductible would cost approximately $800 to $950 per fill before reaching an out-of-pocket maximum. Most plans cap annual out-of-pocket costs, so patients who reach their cap (typically $3,000 to $8,700 for individual commercial plans in 2025) pay nothing more for covered drugs for the rest of the plan year. [6]

Without coverage or pending appeal

Without insurance, a 28-day Forteo pen costs approximately $3,200 to $3,800 at retail pharmacies. [2] GoodRx and similar discount programs do not typically produce significant reductions for specialty biologics, though prices can vary by pharmacy.

Eli Lilly patient assistance options

Eli Lilly operates two programs relevant to Forteo access. The Forteo Savings Card (for commercially insured patients who meet income criteria) may reduce monthly cost-sharing significantly. The Lilly Cares Foundation Patient Assistance Program provides free medication to uninsured or underinsured patients who meet income-based eligibility thresholds, generally at or below 400% of the federal poverty level. [15] Patients can initiate enrollment through the Lilly Cares Foundation website or by calling 1-800-545-5979.

Alternatives to Forteo That Harvard Pilgrim Covers More Readily

If Forteo is denied or step therapy is required, clinicians and patients should be aware of the full coverage field for osteoporosis treatment under HPHC. [16]

Bisphosphonates (preferred first-line, Tier 1 or 2)

Generic alendronate 70 mg/week and generic risedronate 35 mg/week are on virtually every HPHC formulary at the lowest cost tier, typically $5 to $15 per month with no PA required. The ACE trial and multiple meta-analyses confirm alendronate reduces vertebral fracture risk by approximately 47% over 3 years in postmenopausal women with osteoporosis. [8] [17]

Denosumab (Prolia, 60 mg subcutaneous every 6 months)

Denosumab is generally on a preferred specialty tier and may require PA but faces fewer step therapy barriers than teriparatide. The FREEDOM trial (N=7,808) showed denosumab reduced new vertebral fractures by 68% over 36 months versus placebo. [18] Denosumab is also approved for men on androgen deprivation therapy and for glucocorticoid-induced osteoporosis.

Abaloparatide (Tymlos, 80 mcg/day subcutaneous)

Abaloparatide is a PTH-related protein analogue with a similar mechanism to teriparatide and the same 24-month lifetime limit. The ACTIVE trial (N=2,463) showed abaloparatide reduced new vertebral fractures by 86% versus placebo at 18 months (P<0.001). [19] Some Harvard Pilgrim plans tier abaloparatide differently from teriparatide, so it is worth checking whether abaloparatide has a more favorable PA pathway for a specific patient.

Romosozumab (Evenity, 210 mg subcutaneous monthly for 12 months)

Romosozumab is a sclerostin inhibitor with a dual anabolic and antiresorptive mechanism. The ARCH trial (N=4,093) demonstrated that romosozumab followed by alendronate reduced hip fractures by 38% versus alendronate alone at 24 months. [20] Coverage under HPHC is variable; romosozumab carries an FDA boxed warning for increased cardiovascular risk, which limits eligibility and PA approval in patients with prior MI or stroke. [21]

HealthRX Osteoporosis Coverage Decision Framework: When teriparatide PA is denied under a Harvard Pilgrim plan, the prescribing clinician should sequence the response as follows. Step 1: confirm the denial reason in writing and request the plan's clinical criteria. Step 2: if step therapy is the barrier and the patient is very high risk (T-score at or below -3.0, or two or more prior fragility fractures), invoke the Massachusetts step therapy override statute in the Level 1 appeal. Step 3: if the denial cites a non-covered indication, verify the patient's diagnosis against FDA-approved indications for Forteo. Step 4: if the internal appeal fails, file for external IRO review simultaneously with a Lilly Cares Foundation enrollment application to avoid a treatment gap.

Harvard Pilgrim Medicare Advantage and Part D Coverage for Forteo

Medicare Advantage plans sold by HPHC follow CMS formulary rules. Under Part D, specialty drugs can appear on Tier 5 (specialty) or, in some plans, Tier 4 (non-preferred brand). The 2025 Medicare Part D redesign under the Inflation Reduction Act caps annual out-of-pocket spending at $2,000 for all Part D enrollees, which meaningfully changes the calculus for very expensive drugs like Forteo. [6]

Exception request process for Medicare Part D

If teriparatide is not covered under a specific HPHC Medicare Part D plan, the patient or prescriber can file a formulary exception request. The prescriber must document that all covered alternatives are medically inappropriate for the specific patient. CMS requires the plan to respond to standard exception requests within 72 hours and expedited requests within 24 hours. [13]

Low-income subsidy (LIS / Extra Help) impact

Medicare beneficiaries who qualify for the Part D Low-Income Subsidy (LIS) pay significantly reduced cost-sharing for specialty drugs, with copays capped at $11.20 for generic and $35 for brand-name drugs in 2025. For Forteo, LIS qualification can reduce the financial barrier substantially. [6]

Key Numbers to Know Before Calling Harvard Pilgrim

Keeping the following data points ready before calling HPHC's pharmacy benefit line or initiating a PA speeds up the process considerably.

• HPHC pharmacy benefit and PA line: 1-888-333-4742 (commercial); for Medicare plans, the member ID card carries the plan-specific number.
• Forteo NDC (for PA forms): 00002-8476-01 (3 mL pen, 20 mcg/dose Eli Lilly).
• FDA NDA number for Forteo: 021318. [1]
• ICD-10-CM codes most commonly used: M81.0 (age-related osteoporosis without current pathological fracture), M80.08XA (age-related osteoporosis with current pathological fracture, vertebra), M81.6 (localized osteoporosis), M80.80XA (other osteoporosis with current pathological fracture).
• FRAX tool URL for clinician use: www.sheffield.ac.uk/FRAX (also linked from the National Osteoporosis Foundation site at bonehealthandosteoporosis.org). [3]